ISPOR Europe 2026
8 November 2026 – 11 November 2026
Austria Center Vienna, Vienna, Austria
ISPOR Europe 2026, organised by ISPOR (The Professional Society for Health Economics and Outcomes Research), is a conference for health economics and outcomes research (HEOR) held 8-11 November 2026 at the Austria Center Vienna under the theme "Shaping the Future of Access Through Science and Policy". It brings together researchers and academics, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers and patient organisations, with a pre-conference short course programme followed by a three-day scientific programme of plenary sessions, spotlight sessions, issue panels, workshops, ISPOR forums, research podiums and poster sessions spanning HEOR topics such as health technology assessment, economic evaluation, real-world evidence and patient-centred research.
171 sessions · 425 speakers
Organiser (1)
Media Partner (1)
Sponsors (8)
Thermo Fisher · Analysis Group · Wiley · Novo Nordisk · Veradigm · Datavant · Eli Lilly and Company · Initiate
Exhibitors (14)
Ipsos · IQVIA · Thermo Fisher · ZS Associates · RWS · Analysis Group · Limina · Veradigm · Datavant · Helpware · Initiate · Tune Insight · University of Sheffield · EY
Agenda
- Reimbursement Systems for Pharmaceuticals in Europe 8 November 2026
- Applied Generative AI for HEOR: Introduction 8 November 2026
- Prompt Engineering for HEOR: Practical Skills and Use Cases for HEOR Professionals 8 November 2026
- Health Economic Modeling in R for Decision Making: Assessment, Adaptation, and AI-Assisted Validation 8 November 2026
- Developing Decision-Grade Real-World Evidence 8 November 2026
- Risk-Sharing/Performance-Based Arrangements in Developing Countries 8 November 2026
- Applied Generative AI for HEOR: Robust Architectures 8 November 2026
- Integrating Patient, Payer, and Investor Perspectives on Valuing Innovative Medicines for Orphan Diseases 8 November 2026
- Causal Inference and Causal Estimands from Target Trial Emulations Using Evidence from Real-World Observational Studies and Clinical Trials 8 November 2026
- Practical Applications of Large Language Models for Real-World Evidence Generation and HEOR 8 November 2026
- Designing a Patient-Centered Strategy for Drug Development and Value 8 November 2026
- Plenary Session 1: The Science of What Matters: Rethinking Value in Healthcare 9 November 2026
- Plenary Session 1: Opening Remarks and Special Address 9 November 2026
- ISPOR Central and Eastern Europe (CEE) Consortium Meeting 9 November 2026
- ISPOR Real-World Evidence Special Interest Group Meeting 9 November 2026
- Converting Vaccine Evidence to Policy 9 November 2026
- The Historical Linear Life Science Model is Dead and Requires Rethinking to Adapt to a Rapidly Changing Ecosystem 9 November 2026
- Early Value Assessment When There Are Multiple External Comparators: Introducing Value-Based Decision Boundary Analysis (VB-DBA) 9 November 2026
- When Global Policy Agendas Collide – Evidence, Value, and Pricing Tensions at the Intersection of EU and US Reform 9 November 2026
- Navigating Europe’s New Era of Health Policy Reform: How Will the EU HTA Regulation, Pharmaceutical Legislation Revision, Critical Medicines Act, and Biotech Act Shape Medicines Development and Patient Access? 9 November 2026
- Beyond the Index Event: Aligning Hospital Decision-Making with Expanded Value Measures for Medical Devices and Diagnostics 9 November 2026
- Who Decides Which Covariates Matter? Aligning Regulatory and HTA Perspectives in Indirect Treatment Comparisons 9 November 2026
- Poster Session 1 9 November 2026
- Humans at the Helm: Navigating Increasing AI Autonomy in HEOR and HTA 9 November 2026
- Capturing Patient and Caregiver Experiences in Psychological and Cognitive Conditions 9 November 2026
- Patient-Reported Outcomes in Federated Real-World Data: Infrastructure Ready, Evidence Fit for HTA? 9 November 2026
- HEOR Impact Cases Poster Tour 9 November 2026
- Oncology Poster Tour 9 November 2026
- The Accidental FX Trader: How United States MFN Pricing Reshapes Global Launch Strategy and Access 9 November 2026
- ISPOR Ukraine, Poland, and Hungary Joint Meeting: Strengthening Regional Collaboration in HTA and Evidence-Informed Healthcare Decision-Making 9 November 2026
- Let’s Get REAL: Real-World Evidence in Action 9 November 2026
- The Non-3G (GENEROUS, GLOBE, GUARD) Pricing Paradox: Navigating the "MFN Trap" Opportunities and Risk in Latin America, the Middle East, and Asia 9 November 2026
- How Can HTA and Regulatory Guidelines and Reviews Strengthen the Case for More Patient Centered Evidence Creation? 9 November 2026
- One JCA, Many Decisions: Building an Evidence Strategy for Portability Across Europe 9 November 2026
- Advancing Evidence-Based Medicine with Generative AI 9 November 2026
- ISPOR Strategic Dialogues: Integrated Evidence Generation Across the Product Lifecycle 9 November 2026
- SMDM-ISPOR Joint Initiative in Health Decision Modelling Agentic AI for Transparent, Reproducible, and Trustworthy Decision Models 9 November 2026
- AI in HEOR: Advancing Evidence Generation for Joint Clinical Assessment 9 November 2026
- How Early Is Early Enough? Rethinking Evidence Planning for Today's Global Access Challenges 9 November 2026
- Spotlight on Joint Clinical Assessments: Learnings to Date, Looking Ahead at Rare Indications, and AI Applications to Enhance Evidence Generation 9 November 2026
- From Subject-Matter Brilliance to Real Impact 9 November 2026
- ISPOR Medical Devices and Diagnostics Special Interest Group Meeting 9 November 2026
- Exploring SUSTAIN-HTA: Resources, Learning and Fellowship Opportunities 9 November 2026
- Reading Between the Endpoints: Translating Trials from Regulatory Estimands to HTA/JCA Decision Making 9 November 2026
- Are Patient Values Genuinely Shaping Value Assessment, or Do They Remain Acknowledged but Underutilized? 9 November 2026
- The Future of Causal Inference: How Large (or Small) Role Will AI Play? 9 November 2026
- First Wave, First Lessons: Multi-Stakeholder Insights from the initial Joint Clinical Assessments Under the European Regulation on Health Technology Assessment 9 November 2026
- Tackling Societal Challenges Facing Public Health 9 November 2026
- How Will the Most Favored Nation (MFN) Policy Influence Medicines Pricing and Access in Europe and How Should Policy Makers Respond? 9 November 2026
- COAlescing the Oncology COA Strategy: A Provocative Look at Why Pncology COA Strategies Often Fail - and How to Fix Them 9 November 2026
- Should Real-World Evidence Play a Role in Reimbursement Decisions on Decommissioning Health Technologies? 9 November 2026
- Health Utility Measurement: EQ-5D Innovations and Broader Perspectives 9 November 2026
- Beware (non-proportional) Hazard! Alternative Routes for Dealing with Time-Varying Treatment Effects in Evidence Synthesis for Health Technology Assessment (HTA) Decision Making 9 November 2026
- ISPOR Spain Chapter Meeting 9 November 2026
- Real-Time Intelligence: AI-Enabled Insights to Drive Evidence Strategy 9 November 2026
- From Policy to Practice: The Evolution of HEOR and Healthcare Decision-Making in China — Experiences, Insights, and Lessons Learned 9 November 2026
- Preparing Orphan Medicinal Products for JCA: Strengthening the Evidence Package 9 November 2026
- The HEMA Debate: The Value Judgements Involved in Deciding How “Value” Is Measured: A Value in Health Forum 9 November 2026
- From HTA to Public Health: Rethinking Value in Obesity 9 November 2026
- One Assessment, Many Decisions: The Future of Country-Level HTA After JCA 9 November 2026
- Shaping the Future of HEOR: A Special Preview of ISPOR's Updated Science Strategy 9 November 2026
- Informing Healthcare Investment Through a Patient-Centered Lens 9 November 2026
- Updating HTA Methods in Central and Eastern Europe: Can National Guidelines Converge While Remaining Locally Relevant? 9 November 2026
- From Value Assessment to Delivery Reality: Integrating HEOR and Health Systems Perspectives in Coverage Decisions for GLP-1 Therapies 9 November 2026
- Patient-Centered Evidence Poster Tour 9 November 2026
- Poster Session 2 9 November 2026
- Artificial Intelligence Poster Tour 9 November 2026
- Introducing ISPOR Italy: A New Chapter for the Future 9 November 2026
- Artificial Intelligence for Evidence Generation and Synthesis 9 November 2026
- Joint Clinical Assessment (JCA) and Pan-European Solidarity-Based Reimbursement Model (PANSOL) - Is Collaborative Assessment Meeting the Needs of EU Member States? 9 November 2026
- Integrating Environmental Sustainability into HTA: Global Policy Archetypes and Future Directions for Access Decision-Making 9 November 2026
- Agentic AI Governance: How to Balance Innovation and Guidance 9 November 2026
- Whole Health at Risk: Does EU Joint Clinical Assessment Conflict with Europe’s Antimicrobial Resistance Ambitions? 9 November 2026
- EU HTA System Readiness for Orphan Medicinal Products ahead of 13 January 2028 9 November 2026
- ICH E22 – General Considerations for Patient Preference Studies: Are We Ready to Move from Guidance to Practice? 9 November 2026
- Beyond “Using RWE”: What It Takes to Make Real-World Evidence Decision-Grade for HTA? 9 November 2026
- Case Studies in Med Tech Evaluation 9 November 2026
- ISPOR Digital Health Special Interest Group Meeting 9 November 2026
- Mixture Cure Models: Do They Create More Issues Than They are Trying to Solve? 9 November 2026
- Plenary Session 2: Presidential Address, and Keynote Speaker 10 November 2026